A global respiratory perspective on the COVID-19 pandemic: commentary and action proposals

Teresa To¹, Giovanni Viegi², Alvaro Cruz³, Luis Taborda-Barata⁴, Innes Asher⁵, Digambar Behera⁶, Kazi Bennoor⁷, Louis-Philippe Boulet⁸, Jean Bousquet⁹, Paulo Camargos¹⁰, Claudia Conceiçao¹¹, Sandra Gonzalez Diaz¹², Asma El-Sony¹³, Marina Erhola¹⁴, Mina Gaga¹⁵, David Halpin¹⁶, Letitia Harding¹⁷, Tamaz Maghlakelidze¹⁸, Mohammad Reza Masjedi¹⁹, Yousser Mohammad²⁰, Elizabete Nunes²¹, Bernard Pigearias²², Talant Sooronbaev²³, Rafael Stelmach²⁴, Ioanna Tsiligianni²⁵, Le Thi Tuyet Lan²⁶, Arunas Valiulis²⁷, Chen Wang²⁸, Sian Williams²⁹, Arzu Yorgancioglu³⁰

Affiliations

¹ The Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada teresa.to@sickkids.ca.
² CNR Institutes of Clinical Physiology, Pisa, and Biomedical Research and Innovation, Palermo, Italy.
³ ProAR Foundation and Federal University of Bahia, Salvador, Brazil.
⁴ Dept of Allergy and Clinical Immunology, Cova da Beira University Hospital Centre, Covilhã, Portugal.
⁵ Dept of Paediatrics and Child Health, University of Auckland, Auckland, New Zealand.
⁶ OSD, All India Institutes of Medical Sciences (AIIMS), Raebareli, India.
⁷ Dept of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh.
⁸ Québec heart and Lung Institute, Laval University, Québec, QC, Canada.
⁹ MACVIA-France, Fondation Partenariale FMC VIA-LR, CHRU Arnaud de Villeneuve, Montpellier, France.
¹⁰ Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Pediatria, Belo Horizonte, Brazil.
¹¹ Instituto de Higiene e Medicina Tropical, Institute of Tropical Medicine and Hygiene, NOVA University of Lisbon, Lisbon, Portugal.
¹² Hospital Universitario y Facultad de Medicina, Monterrey Nuevo Leon, Mexico.
¹³ Public Health Epidemiological Laboratory [Epi Lab] for Research and Development, Khartoum, Sudan.
¹⁴ Division of Health and Social Service, Finnish Institute for Health and Welfare, Helsinki, Finland.
¹⁵ 7th Respiratory Medicine Dept, Asthma Cen, Athens Chest Hospital, Athens, Greece.
¹⁶ University of Exeter Medical School, College of Medicine and Health, Exeter, UK.
¹⁷ Asthma and Respiratory Foundation, Wellington, New Zealand.
¹⁸ Ivane Javakhishvili Tbilisi State University, Pulmonology Dept, Chapidze Emergency Cardiology Center, Tbilisi, Georgia.
¹⁹ Shahid Beheshti University of Medical Sciences, Tehran, Iran.
²⁰ National Center for Research inn Chronic Respiratory Diseases, Tishreen University, School of Medicine, Latakia, Syria.
²¹ Pulmonology Dept, Maputo Central Hospital, Maputo, Mozambique.
²² Espace Francophone de Pneumologie, La Maison du poumon, Paris, France.
²³ Kyrgyzstan National Centre of Cardiology and Internal Medicine, Euro-Asian Respiratory Society, Bishkek, Kyrgyzstan.
²⁴ ProAR Foundation and Heart Institute (InCor) Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
²⁵ International Primary Care Respiratory Group; Dept of Social Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece.
²⁶ Respiratory Care Center, University Medical Center, Ho Chi Minh City, Vietnam.
²⁷ Clinic of Children's Diseases, Institute of Clinical Medicine, and Dept of Public Health, Institute of Health Sciences, Vilnius University, Vilnius, Lithuania.
²⁸ Peking Union Medical College, Chinese Academy of Medical Science, Beijing, China.
²⁹ International Primary Care Respiratory Group, London, UK.
³⁰ Dept of Pulmonology, Medical Faculty, Celal Bayar University, Manisa, Turkey.

PMID: 32586874
PMCID: PMC7315811
DOI: 10.1183/13993003.01704-2020

Editorial

A global respiratory perspective on the COVID-19 pandemic: commentary and action proposals

Teresa To et al. Eur Respir J. 2020.

. 2020 Jul 23;56(1):2001704.

doi: 10.1183/13993003.01704-2020. Print 2020 Jul.

Authors

Affiliations

¹ The Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada teresa.to@sickkids.ca.
² CNR Institutes of Clinical Physiology, Pisa, and Biomedical Research and Innovation, Palermo, Italy.
³ ProAR Foundation and Federal University of Bahia, Salvador, Brazil.
⁴ Dept of Allergy and Clinical Immunology, Cova da Beira University Hospital Centre, Covilhã, Portugal.
⁵ Dept of Paediatrics and Child Health, University of Auckland, Auckland, New Zealand.
⁶ OSD, All India Institutes of Medical Sciences (AIIMS), Raebareli, India.
⁷ Dept of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh.
⁸ Québec heart and Lung Institute, Laval University, Québec, QC, Canada.
⁹ MACVIA-France, Fondation Partenariale FMC VIA-LR, CHRU Arnaud de Villeneuve, Montpellier, France.
¹⁰ Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Pediatria, Belo Horizonte, Brazil.
¹¹ Instituto de Higiene e Medicina Tropical, Institute of Tropical Medicine and Hygiene, NOVA University of Lisbon, Lisbon, Portugal.
¹² Hospital Universitario y Facultad de Medicina, Monterrey Nuevo Leon, Mexico.
¹³ Public Health Epidemiological Laboratory [Epi Lab] for Research and Development, Khartoum, Sudan.
¹⁴ Division of Health and Social Service, Finnish Institute for Health and Welfare, Helsinki, Finland.
¹⁵ 7th Respiratory Medicine Dept, Asthma Cen, Athens Chest Hospital, Athens, Greece.
¹⁶ University of Exeter Medical School, College of Medicine and Health, Exeter, UK.
¹⁷ Asthma and Respiratory Foundation, Wellington, New Zealand.
¹⁸ Ivane Javakhishvili Tbilisi State University, Pulmonology Dept, Chapidze Emergency Cardiology Center, Tbilisi, Georgia.
¹⁹ Shahid Beheshti University of Medical Sciences, Tehran, Iran.
²⁰ National Center for Research inn Chronic Respiratory Diseases, Tishreen University, School of Medicine, Latakia, Syria.
²¹ Pulmonology Dept, Maputo Central Hospital, Maputo, Mozambique.
²² Espace Francophone de Pneumologie, La Maison du poumon, Paris, France.
²³ Kyrgyzstan National Centre of Cardiology and Internal Medicine, Euro-Asian Respiratory Society, Bishkek, Kyrgyzstan.
²⁴ ProAR Foundation and Heart Institute (InCor) Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
²⁵ International Primary Care Respiratory Group; Dept of Social Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece.
²⁶ Respiratory Care Center, University Medical Center, Ho Chi Minh City, Vietnam.
²⁷ Clinic of Children's Diseases, Institute of Clinical Medicine, and Dept of Public Health, Institute of Health Sciences, Vilnius University, Vilnius, Lithuania.
²⁸ Peking Union Medical College, Chinese Academy of Medical Science, Beijing, China.
²⁹ International Primary Care Respiratory Group, London, UK.
³⁰ Dept of Pulmonology, Medical Faculty, Celal Bayar University, Manisa, Turkey.

PMID: 32586874
PMCID: PMC7315811
DOI: 10.1183/13993003.01704-2020

Abstract

This paper offers practical and feasible actions to be implemented at patient, healthcare provider and community level to combat COVID-19 while attending, maintaining and strengthening ongoing health management in people with lung diseases https://bit.ly/30yNyhP

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: T. To has nothing to disclose. Conflict of interest: G. Viegi has nothing to disclose. Conflict of interest: A. Cruz has nothing to disclose. Conflict of interest: L. Taborda-Barata reports honoraria from AstraZeneca, Novartis, Menarini and Vitoria Laboratories as payment for giving scientific lectures in the context of training sessions in the respiratory field or allergy, for healthcare professionals. Conflict of interest: M. Asher has nothing to disclose. Conflict of interest: D. Behera has nothing to disclose. Conflict of interest: K. Bennoor has nothing to disclose. Conflict of interest: L-P. Boulet has nothing to disclose. Conflict of interest: J. Bousquet reports personal fees for advisory board work, consultancy and lectures from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi-Aventis, Takeda, Teva and Uriach, and owns shares in KYomed-Innov, outside the submitted work. Conflict of interest: P. Camargos has nothing to disclose. Conflict of interest: C. Conceiçao has nothing to disclose. Conflict of interest: S. Gonzalez Diaz has nothing to disclose. Conflict of interest: A. El-Sony has nothing to disclose. Conflict of interest: M. Erhola has nothing to disclose. Conflict of interest: M. Gaga reports grants and personal fees from Novartis and Menarini, grants from Galapagos and Elpen, personal fees from BMS, MSD and AZ, outside the submitted work. Conflict of interest: D. Halpin reports personal fees from AstraZeneca, Chiesi, GlaxoSmithKline, Novartis, Pfizer and Sanofi, personal fees and non-financial support from Boehringer Ingelheim and Novartis, outside the submitted work. Conflict of interest: L. Harding has nothing to disclose. Conflict of interest: T. Maglakelidze has nothing to disclose. Conflict of interest: M.R. Masjedi has nothing to disclose. Conflict of interest: Y. Mohammad has nothing to disclose. Conflict of interest: E. Nunes has nothing to disclose. Conflict of interest: B. Pigearias has nothing to disclose. Conflict of interest: T. Sooronbaev has nothing to disclose. Conflict of interest: R. Stelmach reports grants from São Paulo Research Foundation and MSD, grants and personal fees from Novartis, grants, personal fees and non-financial support from AstraZeneca and Chiesi, personal fees and non-financial support from Boehringer Ingelheim, outside the submitted work. Conflict of interest: I. Tsiligianni reports grants from Elpen and GSK Hellas, personal fees from Novartis, Boehringer Ingelheim, GSK and Menarini, outside the submitted work. Conflict of interest: L.T. Tuyet Lan has nothing to disclose. Conflict of interest: A. Valiulis has nothing to disclose. Conflict of interest: C. Wang has nothing to disclose. Conflict of interest: S. Williams has nothing to disclose. Conflict of interest: A. Yorgancioglu has nothing to disclose.

Cited by

Vaccination with outer membrane vesicles from Neisseria Meningitidis and SBa15, SBa16 mesoporous silica associated with SARS-CoV-2 induces protective humoral and cellular response against COVID-19 in mice.
Bernardes BG, Moura AD, Guarnieri JPO, Silva CFMD, Costa HHMD, Silva IGMD, Cordeiro KBB, Báo SN, Prudêncio CR, Lancellotti M. Bernardes BG, et al. Braz J Infect Dis. 2024 Nov-Dec;28(6):104479. doi: 10.1016/j.bjid.2024.104479. Epub 2024 Nov 14. Braz J Infect Dis. 2024. PMID: 39547005 Free PMC article.
COVID-19 and Vaccine Hesitancy: Individual Determinants Among Saudis in Asir Region.
Jan M, Alqahtani M, Amer KA, Althubait B, Aldosari AAS, Al Mudawi AAM. Jan M, et al. Cureus. 2022 Feb 17;14(2):e22331. doi: 10.7759/cureus.22331. eCollection 2022 Feb. Cureus. 2022. PMID: 35317043 Free PMC article.
Chronic respiratory diseases other than asthma in children: the COVID-19 tsunami.
Di Cicco M, Tozzi MG, Ragazzo V, Peroni D, Kantar A. Di Cicco M, et al. Ital J Pediatr. 2021 Nov 6;47(1):220. doi: 10.1186/s13052-021-01155-9. Ital J Pediatr. 2021. PMID: 34742332 Free PMC article. Review.
Impact of COVID-19 on the Most Frequent Middle and Lower Obstructive Airway Diseases/Syndromes in Adult Population.
Tiotiu A. Tiotiu A. Arch Bronconeumol. 2021 Apr;57:7-8. doi: 10.1016/j.arbres.2021.02.006. Epub 2021 Mar 3. Arch Bronconeumol. 2021. PMID: 34629628 Free PMC article. No abstract available.
Potential role of marine species-derived bioactive agents in the management of SARS-CoV-2 infection.
Asif M, Saleem M, Yaseen HS, Yehya AH, Saadullah M, Zubair HM, Oon CE, Khaniabadi PM, Khalid SH, Khan IU, Mahrukh. Asif M, et al. Future Microbiol. 2021 Nov;16(16):1289-1301. doi: 10.2217/fmb-2021-0024. Epub 2021 Oct 25. Future Microbiol. 2021. PMID: 34689597 Free PMC article.

See all "Cited by" articles

References

1. Zhu N, Zhang D, Wang W, et al. . A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727–733. doi:10.1056/NEJMoa2001017 - DOI - PMC - PubMed
1. World Health Organization Coronavirus Disease (COVID-19) Pandemic. 2020 [cited 2020 April 19]; www.who.int/emergencies/diseases/novel-coronavirus-2919 Date last accessed: 19 April 2020.
1. European Centre for Disease Control and Prevention. COVID-19 Global Overview. https://qap.ecdc.europa.eu/public/extensions/COVID-19/COVID-19.html Date last accessed: 19 April 2020.
1. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1736–1788. doi:10.1016/S0140-6736(18)32203-7 - DOI - PMC - PubMed
1. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1789–1858. doi:10.1016/S0140-6736(18)32279-7 - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A global respiratory perspective on the COVID-19 pandemic: commentary and action proposals

Affiliations

A global respiratory perspective on the COVID-19 pandemic: commentary and action proposals

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous